FSL2 Post Approval Study for Pediatric and Young Adults Patients

Diabete Mellitus Clinical Trial

Official title:

FreeStyle Libre 2 Flash Glucose Monitoring System Intervention Phase Study- FreeStyle Libre 2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04959552
• Other study ID #: ADC-US-PMS-20196
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: December 30, 2024

Study information

• Verified date: July 2023
• Source: Abbott Diabetes Care
• Contact: Mohamed Nada, PhD
• Phone: 510-749-5416
• Email: adc.clinical[@]abbott.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations.

Description:

Approximately 550 pediatric and young adult subjects aged 4-30 years with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes will be enrolled in the study. Subjects and/or their caregivers will utilize he FreeStyle Libre 2 Flash Glucose Monitoring System for managing diabetes for 6 months. Subjects and/or their caregivers will maintain a diary/log book of Adverse Events experienced during the duration of the study. Assessment of Adverse Events will occur via self reporting at each monthly visit and/or phone call.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 550
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 30 Years

Eligibility

Inclusion Criteria:

1. Subject must be 4 - 30 years of age.

2. Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment.

3. Subject is currently using Self Monitoring of Blood Glucose (SMBG) for managing their diabetes.

4. Subject has completed participation in clinical study ADC-US-PMS-20194 or has at least six (6) months of medical history hypoglycemia or hyperglycemia requiring healthcare professional intervention.

5. Subject and/or caregiver must be able to read and understand English.

6. In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

7. Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.

Exclusion Criteria:

8. Subject has previously used a continuous glucose monitoring system to manage their diabetes within the last six (6) months.

9. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

10. Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment.

11. Subject is on dialysis at the time of enrollment.

12. Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.

13. Subject currently is participating in another clinical trial.

14. Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Related Conditions & MeSH terms

• Diabete Mellitus
• Diabetes Mellitus

Intervention

Device:
• FreeStyle Libre 2
The FreeStyle Libre 2 Flash Glucose Monitoring

Locations

Country	Name	City	State
United States	The Children's Mercy Hospital	Kansas City	Missouri
United States	The DOCS	Las Vegas	Nevada
United States	Yale Pediatric Endocrinology Clinic	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations	Incidence rate of severe hypoglycemic occurrences requiring health care professional (HCP) intervention including EMT assistance, hospital/clinic visit and/or hospitalization and moderate hypoglycemia in which the patient required the assistance of another person (e.g. as a result of confusion, coma, or seizure) during the study will be collected.; The incidence rate of severe hypoglycemia associated with FSL2 use from this study will be compared with the incidence rate observed from self-monitoring blood glucose (SMBG) use observed during the prior 6 months.	Six Months